Premium
Influence of quercetin supplementation on disease risk factors in community‐dwelling adults
Author(s) -
Knab Amy M.,
Shanely R. Andrew,
Henson Dru A.,
Jin Fuxia,
Heinz Serena A.,
Austin Melanie D.,
Nieman David C.
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.721.1
Subject(s) - quercetin , blood pressure , lipid profile , renal function , creatinine , medicine , placebo , c reactive protein , endocrinology , cholesterol , chemistry , inflammation , biochemistry , pathology , antioxidant , alternative medicine
In vitro and animal data indicate quercetin has antioxidative and anti‐inflammatory functions and lowers disease risk factors, but data in humans is limited. This study investigated the effect of quercetin supplementation (500 mg/d, or 1000 mg/d) on disease risk factors in a large group of adults (n=1,002, 60% female, 40% male) varying widely in age and BMI. Randomized groups (placebo, PL; Q500; or Q1000) were supplemented for 12 weeks. Plasma quercetin, inflammatory markers (C‐reactive protein, CRP, and five cytokines), diagnostic blood chemistries, blood pressure, and blood lipid profiles were measured. No differences in blood chemistries were found except for a small decrease in serum creatinine and increase in glomerular filtration rate in Q‐500 and Q‐1000 groups compared to PL. A small but significant decrease in mean arterial blood pressure (MAP) was measured for Q500 and Q1000 groups compared to PL. The change in serum total cholesterol was different between Q500 and PL groups, and there was a small but significant decrease in HDL in Q1000 compared to PL. Change in IL‐6 differed slightly between Q1000 and PL groups (interaction effect, P=0.021), but change in CRP and other inflammatory measures did not differ between groups. Two high doses of quercetin had a negligible influence on disease risk factors, with the most notable finding being a decrease in MAP. Supported by grants from Coca‐Cola and Quercetin Pharma